Nanjing Vazyme Biotech Co Ltd (688105) - Net Assets
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has net assets worth CN¥3.84 Billion CNY (≈ $562.02 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.01 Billion ≈ $732.59 Million USD) and total liabilities (CN¥1.17 Billion ≈ $170.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Nanjing Vazyme Biotech Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.84 Billion |
| % of Total Assets | 76.72% |
| Annual Growth Rate | 59.39% |
| 5-Year Change | 195.99% |
| 10-Year Change | N/A |
| Growth Volatility | 197.52 |
Nanjing Vazyme Biotech Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 688105 asset base for the complete picture of this company's asset base.
Annual Net Assets for Nanjing Vazyme Biotech Co Ltd (2017–2024)
The table below shows the annual net assets of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024. For live valuation and market cap data, see 688105 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
-2.13% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
-12.64% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
+11.75% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
+209.77% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
+566.12% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
+20.44% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
+10.12% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Vazyme Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 97273842973.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥938.00 Million | 23.78% |
| Common Stock | CN¥402.13 Million | 10.19% |
| Other Components | CN¥2.61 Billion | 66.03% |
| Total Equity | CN¥3.95 Billion | 100.00% |
Nanjing Vazyme Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Luye Pharma Group Ltd
F:LUP
|
$1.18 Billion |
|
Hnac Technology Co Ltd
SHE:300490
|
$1.18 Billion |
|
Shanghai Hugong Elec(Group)
SHG:603131
|
$1.18 Billion |
|
RITES Limited
NSE:RITES
|
$1.18 Billion |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
$1.18 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
$1.18 Billion |
|
Johnson Health Tech Co Ltd
TW:1736
|
$1.18 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Vazyme Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,029,387,759 to 3,945,243,056, a change of -84,144,703 (-2.1%).
- Net loss of 18,093,805 reduced equity.
- Dividend payments of 80,363,098 reduced retained earnings.
- Share repurchases of 104,395,355 reduced equity.
- Other factors increased equity by 118,707,555.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-18.09 Million | -0.46% |
| Dividends Paid | CN¥80.36 Million | -2.04% |
| Share Repurchases | CN¥104.40 Million | -2.65% |
| Other Changes | CN¥118.71 Million | +3.01% |
| Total Change | CN¥- | -2.09% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Vazyme Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 47.64x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.42 | CN¥20.20 | x |
| 2018-12-31 | CN¥0.47 | CN¥20.20 | x |
| 2019-12-31 | CN¥0.50 | CN¥20.20 | x |
| 2020-12-31 | CN¥3.75 | CN¥20.20 | x |
| 2021-12-31 | CN¥11.38 | CN¥20.20 | x |
| 2022-12-31 | CN¥11.56 | CN¥20.20 | x |
| 2023-12-31 | CN¥10.22 | CN¥20.20 | x |
| 2024-12-31 | CN¥10.90 | CN¥20.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Vazyme Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.31%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.28x
- Recent ROE (-0.46%) is below the historical average (13.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 2.42% | 3.24% | 0.60x | 1.25x | CN¥-11.44 Million |
| 2018 | 0.63% | 0.61% | 0.68x | 1.51x | CN¥-15.57 Million |
| 2019 | 12.90% | 9.61% | 0.83x | 1.62x | CN¥5.79 Million |
| 2020 | 61.67% | 52.52% | 0.97x | 1.21x | CN¥688.49 Million |
| 2021 | 16.43% | 36.30% | 0.41x | 1.12x | CN¥265.56 Million |
| 2022 | 12.89% | 16.65% | 0.59x | 1.30x | CN¥133.35 Million |
| 2023 | -1.76% | -5.52% | 0.22x | 1.43x | CN¥-473.90 Million |
| 2024 | -0.46% | -1.31% | 0.27x | 1.28x | CN¥-412.62 Million |
Industry Comparison
This section compares Nanjing Vazyme Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,387,359,426
- Average return on equity (ROE) among peers: 2.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Vazyme Biotech Co Ltd (688105) | CN¥3.84 Billion | 2.42% | 0.30x | $1.18 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $948.24 Million | -53.63% | 0.17x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $304.67 Million | -9.25% | 1.53x | $444.78 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.06 Billion | 8.06% | 0.08x | $444.44 Million |
| Chengzhi Shareholding Co Ltd (000990) | $15.52 Billion | 0.71% | 0.30x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.87 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.25 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $5.41 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $568.58 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.91 Billion |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more